Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00330-024-11325-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mapping the knowledge landscape of the PET/MR domain: a multidimensional bibliometric analysis.
Eur J Nucl Med Mol Imaging
January 2025
Huashan Hospital and Human Phenome Institute, Fudan University, 220 Handan Road, Shanghai, 200433, China.
Objective: This study aims to conduct a bibliometric analysis to explore research trends, collaboration patterns, and emerging themes in the PET/MR field based on published literature from 2010 to 2024.
Methods: A detailed literature search was performed using the Web of Science Core Collection (WoSCC) database with keywords related to PET/MR. A total of 4,349 publications were retrieved and analyzed using various bibliometric tools, including VOSviewer and CiteSpace.
Characterization of DNA methylation clock algorithms applied to diverse tissue types.
Aging (Albany NY)
January 2025
Department of Public Health Sciences, University of Chicago, Chicago, IL 60615, USA.
Background: DNA methylation (DNAm) data from human samples has been leveraged to develop "epigenetic clock" algorithms that predict age and other aging-related phenotypes. Some DNAm clocks were trained using DNAm obtained from blood cells, while other clocks were trained using data from diverse tissue/cell types. To assess how DNAm clocks perform across non-blood tissue types, we applied DNAm algorithms to DNAm data generated from 9 different human tissue types.
View Article and Find Full Text PDFEnhanced pharmacokinetic approach for anastrozole in macromolecule-based silk fibroin nanoparticles incorporated injectables for estrogen-positive breast cancer therapy.
J Drug Target
January 2025
Department of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be University), Mangalore, Karnataka, 575018, India.
Breast cancer (BC) is a substantial reason for cancer-related mortality among women across the globe. Anastrozole (ANS) is an effective orally administered hormonal therapy for estrogen+ (ER+) BC treatment. However, several side effects and pharmacokinetic limitations restricted its uses in BC treatment.
View Article and Find Full Text PDFHuman Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights.
Curr Oncol Rep
January 2025
Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa City, Chiba, Japan.
Purpose Of Review: Human epidermal growth factor receptor 2 (HER2) is a critical target in advanced gastric cancer (AGC). This review highlights the current treatment landscape, lessons learned from past clinical trials, and prospects for future treatment strategies for HER2-positive AGC.
Recent Findings: Trastuzumab had been the standard treatment for HER2-positive AGC for a decade, and subsequently, trastuzumab deruxtecan, an antibody-drug conjugate (ADC), emerged with an impressive response.
The optimal neoadjuvant treatment strategy for HR+/HER2 + breast cancer: a network meta-analysis.
Sci Rep
January 2025
Department of Breast, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
The efficacy of neoadjuvant therapy varies significantly with hormone receptor (HR) status for patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC). Despite extensive research on HER2 + BC, the optimal neoadjuvant strategy for HR+/HER2 + BC remains inconclusive. This study aimed to identify the optimal neoadjuvant regimen for HR+/HER2 + BC treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!